Skip to content

Barnes & Noble Education BNED Common stock issuance for private placement

Common stock issuance for private placement at other companies

FCR
FutureCrest Acquisition FCRS
$7M
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
$15.59M
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$0-100%
Barnes & Noble Education logo
Barnes & Noble EducationBNED
$0
KBO
Karbon Capital Partners Corp. Class A Ordinary SharesKBON
$8.9M
Vor Biopharma logo
Vor BiopharmaVOR
$75M

Other financials

Income statement

See full
Revenue$515.1M+11.3%
Gross profit$96.1M+2.5%
Operating income$14.6M-22.7%
Net income$6.7M-62.9%
EPS (diluted)$0.19-67.8%

Balance sheet

See full
Cash & equivalents$10.1M-39.4%
Total debt$316.0M-13.2%
Total equity$290.0M-1.0%
Total assets$1.1B+3.4%

Cash flow

See full
Operating cash flow-$29.4M+29.9%
CapEx$3.7M+34.6%
Free cash flow-$33.1M+25.9%

Valuation

See full
Market cap$460.6M+21.9%
Enterprise value$766.47M+17.5%
P/S0.3×0.0×

Profitability

See full
Gross margin20.3%-0.3pp
Operating margin-0.3%-0.1pp
Net margin-0.6%-0.3pp
FCF margin-1.6%-0.5pp

Returns & leverage

See full
Return on equity-3.3%-1.6pp
Debt / equity1.1×-0.2×
Current ratio1.4×0.0×

Where this comes from

Reported directly by Barnes & Noble Education in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.

The official record: Barnes & Noble Education’s 10-Q, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Barnes & Noble Education's common stock issuance for private placement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Barnes & Noble Education's common stock issuance for private placement?
Barnes & Noble Education (BNED) reported common stock issuance for private placement of $0 in Q4 2025.
What does common stock issuance for private placement mean?
Represents cash inflows generated from the sale of equity securities directly to private investors rather than through public markets. This is often used to assess external capital support and potential dilution for existing shareholders.